Product
Cadonilimab plus Pemetrexed and Anlotinib
1 clinical trial
1 indication
Indication
Lung CancerClinical trial
A Phase II Clinical Trial Evaluating the Efficacy of Cadonilimab in Combination With Pemetrexed and Anlotinib for Treatment of Elderly Patients With T790M-negative Advanced Non-squamous Non-small Cell Lung Cancer Following Resistance to EGFR-TKI.Status: Recruiting, Estimated PCD: 2024-12-01